CADTH | Evidence Driven
CADTH | Evidence Driven

everolimus

Details

Files
Generic Name:
everolimus
Project Status:
Active
Therapeutic Area:
Renal angiomyolipoma associated with tuberous sclerosis complex
Manufacturer:
N/A
Call for patient/clinician input open:
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Sub Line:
Non-Oncology Single Drug Reviews (Non-Sponsored)
Project Number:
SX0814-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
Renal angiomyolipoma associated with TSC.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open12-Jul-23
Call for patient/clinician input closed01-Sep-23
Call for industry input open13-Jul-23
Call for industry input closed01-Sep-23
Submission received06-Jul-23
Clarification:

- Patient input submission received from TSC Canada

Review initiated18-Jul-23
Expert committee meeting (initial)01-Feb-24
Draft recommendation posted for stakeholder feedback28-Feb-2024
End of feedback period13-Mar-2024

Files

Recommendation and Reasons View PDF
Responses to Questions From the Drug Programs View PDF

Related Content

Last Updated : April 18, 2024